Trends in Immunology
ReviewImmunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses
Section snippets
The Immune Profile of Solid Tumors Can Determine the Efficacy of Immunotherapy
Our immune system is able to respond to invading pathogens and initiate a protective immune response. Although malignant cells are more similar to the host than pathogens are, they still differ genetically, metabolically, and morphologically from normal cells and, therefore, can be recognized by the adaptive immune system, a trait called immunogenicity (see Glossary). In Box 1, we provide more information about processes involved in antitumor immunity. Immunotherapy is being extensively studied
Immune Checkpoint Inhibition Can Reinvigorate Dysfunctional Antitumor Responses in Immune-infiltrated Tumors
The discovery of immune checkpoints boosted the development of immunotherapeutic strategies against certain cancers. Programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) are well-recognized immune checkpoint receptors that can limit antitumor immunity using distinct mechanisms. CTLA-4 prevents T cell activation by competing with the co-stimulatory molecule CD28 for binding to their common ligands CD80 and CD86 [5]. By contrast, PD-1 induces T cell
TGF-β as a Mediator of Immunosuppression
The secreted cytokine TGF-β is one of the key factors believed to be responsible for immune exclusion and suppression in certain types of cancer, such as pancreatic cancer, nonsmall cell lung cancer, and colon cancer [27., 28., 29.]. In premalignant lesions, TGF-β signaling suppresses tumor growth by inducing apoptosis and inhibiting cell proliferation [30]. However, during tumor progression, tumor cells become insensitive to TGF-β-induced cytostatic effects, and TGF-β functionally switches
Recruiting Tumor-specific Effector T cells Is the First Priority in Immune-desert Tumors
While immune-excluded tumors may benefit from combined checkpoint blockade and TGF-β inhibition, tumors with an immune-desert phenotype are less likely to benefit from this combination therapy [4,54]. Immune-desert tumors are characterized by an absence of T lymphocytes in both the tumor and surrounding stromal regions [4]. The absence of pre-existing antitumor immunity is the first barrier that needs to be overcome before checkpoint inhibitors and TGF-β blockade can be used.
Combining OVs with TGF-β Inhibition to Sensitize Solid Tumors for Immunotherapy
The lack of immunogenicity and the presence of stromal and immunosuppressive barriers are two major hurdles to effective immunotherapy for immune-desert tumors. Therefore, combined modulation of the stromal barrier by TGF-β inhibition and increasing immunogenicity using OVs might be a potent strategy to sensitize immune-desert tumors for T cell-based immunotherapy. Indeed, systemic treatment with a small-molecule TGF-βRI inhibitor in combination with a single intratumoral injection of oncolytic
Concluding Remarks
In this review, we discussed two promising therapeutic strategies to overcome barriers to effective immunotherapy in relation to the tumor immune phenotype. For the classification of tumor immune profiles, we relied on the three main tumor immune phenotypes postulated by Chen and Mellman [3]. We recognize that other classification strategies are possible, and more detailed profiles based on immunophenotyping of tumors are being investigated [21,79]. Immune-infiltrated tumors have an ongoing T
Acknowledgements
We sincerely apologize to authors for not citing their excellent work due to space limitations. This work was financially supported by a PhD fellowship from Leiden University Medical Center (to C.G.), the Dutch Cancer Society Bas Mulder Award 11056 (to N.v.M.), the Cancer Genomics Centre Netherlands (CGC.nl) and the Support Casper campaign by the Dutch foundation ‘Overleven met Alvleesklierkanker’ (supportcasper.nl). All figures were created with BioRender software (BioRender.com).
Glossary
- Bispecific T cell engagers (BiTEs)
- fusion proteins comprising two different single-chain variable fragments of monoclonal antibodies for simultaneous tumor cell binding and T cell activation.
- Cancer-associated fibroblasts (CAFs)
- cell type within the tumor stroma that can promote tumor progression by ECM remodeling and secretion of cytokines.
- Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)
- immune checkpoint receptor that downregulates T cell responses.
- Cytotoxic T lymphocytes (CTL)
- CD8+ effector T
References (119)
Immune checkpoint blockade: a common denominator approach to cancer therapy
Cancer Cell
(2015)The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironment
Semin. Oncol.
(2015)Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6C(low) F4/80(+) extratumoral macrophages
Gastroenterology
(2015)Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation
Cancer Cell
(2012)- et al.
Transforming growth factor-beta signaling in immunity and cancer
Immunity
(2019) Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma
Cell
(2016)HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer
Mol. Ther.
(2005)Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses
Mol. Ther.
(2015)TGF-beta inhibition improves oncolytic herpes viroimmunotherapy in murine models of rhabdomyosarcoma
Mol. Ther. Oncolytics
(2017)- et al.
T cell dysfunction in cancer
Cancer Cell
(2018)
Requirements for CD8 T-cell priming, memory generation and maintenance
Curr. Opin. Immunol.
Targeting the TGFbeta pathway for cancer therapy
Pharmacol. Ther.
The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade
Clin. Cancer Res.
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Nature
Elements of cancer immunity and the cancer-immune set point
Nature
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Nature
Enhancement of antitumor immunity by CTLA-4 blockade
Science
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
J. Exp. Med.
LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
Nat. Immunol.
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
J. Exp. Med.
NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines
Cell
Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells
Cell
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Sci. Transl. Med.
Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers
Mol. Cancer Ther.
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
Clin. Cancer Res.
Genetic basis for clinical response to CTLA-4 blockade in melanoma
N. Engl. J. Med.
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Science
Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade
Nat. Immunol.
Type, Density, and location of immune cells within human colorectal tumors predict clinical outcome
Science
High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status
J. Immunother. Cancer
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Nat. Rev. Drug Discov.
Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors
J. Clin. Invest.
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment
Cancer Res.
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer
Proc. Natl. Acad. Sci. U. S. A.
Topography of cancer-associated immune cells in human solid tumors
eLife
TGF-beta in pancreatic cancer initiation and progression: two sides of the same coin
Cell Biosci.
Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)
Sci. Rep.
Contextual determinants of TGFβ action in development, immunity and cancer
Nat. Rev. Mol. Cell Biol.
Complexities of TGF-beta targeted cancer therapy
Int. J. Biol. Sci.
SMAD4 alteration associates with invasive-front pathological markers and poor prognosis in colorectal cancer
Histopathology
Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma
Braz. J. Med. Biol. Res.
Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells
Nat. Med.
Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation
J. Exp. Med.
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3
J. Exp. Med.
Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes
EMBO Mol. Med.
TGFβ1-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer
Cancer Discov.
Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy
Gene Ther.
α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas
J. Immunother. Cancer
Targeting the TGFbeta pathway with galunisertib, a TGFbetaRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
J. Immunother. Cancer
TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis
Nature
Cited by (51)
Arming oncolytic viruses with bispecific T cell engagers: The evolution and current status
2024, Biochimica et Biophysica Acta - Molecular Basis of DiseaseA promising future in cancer immunotherapy: Oncolytic viruses
2023, European Journal of PharmacologyAdvancements and challenges in oncolytic virus therapy for gastrointestinal tumors
2023, Biomedicine and PharmacotherapyPreexisting immunity: Barrier or bridge to effective oncolytic virus therapy?
2023, Cytokine and Growth Factor Reviews